Full-Time

Regulatory Affairs Manager

Posted on 2/28/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Woking, UK

Hybrid

Hybrid role: 3 days in office per week.

Category
Legal & Compliance (1)
Requirements
  • Degree in life science or science.
  • Experience working within European Regulatory Affairs team, supporting pharmaceutical products and or medical devices or cosmetics.
  • Competent in managing European Procedures (MRP/DCP's).
  • Good communicator, both orally and in written form.
  • Good interpersonal skills.
  • Proven ability to operate within a multifunctional team.
  • Analytical, diligent and accurate.
  • Excellent organisational skills and ability to prioritise.
  • Can do attitude, with strong accountability and ownership.
  • Comfortable with a fast pace and switching between competing priorities.
  • Fluent English.
  • Good knowledge of Microsoft Office.
  • Knowledge of appropriate European regulations and guidelines within the Medicinal Products, Medical Devices and Cosmetics Industry.
  • Experienced in submitting new MAA's for European procedures.
  • Experience of medical devices legislation and working on medical device products.
  • Good working knowledge of pharmaceutical legislation.
  • Additional language skill in addition to fluent English, although not mandatory.
Responsibilities
  • Responsible for managing the regulatory tasks in launching multiple NPD (New product Development) projects as part of a multifunctional team, in accordance with the budget and 5 year plans.
  • Support the European Brand Manager and Central Sourcing Team in assessing potential new Alvita products, the launch in new territories, the evaluation of claims and product attributes of products offered by alternative suppliers.
  • Review and approve Product Specifications and Artwork Management Sheets (AMS), supporting the launch of new Alvita products and update of existing products. Work collaboratively with other colleagues responsible for originating artwork and provide final approval of artwork for allocated projects.
  • Assess the regulatory requirements for products ensuring the product and its labelling are legally compliant.
  • Responsible for becoming the subject matter expert on medical devices within the business and ensuring plans are in place to maintain compliance with the requirements of Medical Devices Regulation (EU) 2017/745 and the in Vitro Diagnostic Medical Device Regulation (EU) 2017/746, in the context of our obligations as an own brand.
  • Ensure that Regulatory Intelligence data is maintained and updated according to the relevant processes. Demonstrate an innovative approach to obtaining market intelligence from suppliers and/or other sources, which can support the brand and local commercial teams in identifying new product opportunities and developing long-term NPD plans. Support the business on regulatory impacting changes, to ensure the necessary steps are taken to mitigate risk to the business.
  • Manage the preparation and submission of the Mutual Recognition Procedure (MRP) and Decentralised Procedure (DCP) Marketing Authorisation Applications (MAAs), involving more than one market.
  • Co-ordinate the management of variations with suppliers and local regulatory teams for European Procedures involving more than one market, ensuring all MAs and products in market meet necessary legal compliance.
  • Manage the preparation and maintenance of Regulatory Compliance Files with the local affiliates and suppliers for European Procedures involving more than one market.
  • Manage the regulatory information within Samarind RMS for European procedures, involving more than one market.
  • Contribute as a “key” member of the team responsible for the successful implementation of Identification of Medicinal Products (IDMP) standards into the IT tools and business processes in accordance with legislative deadlines.
  • Review and approve promotional materials and content on platforms to ensure compliance with relevant legislation and requirements.
  • Support in collaboration with the European Head of Regulatory Affairs and Pharmacovigilance and the local regulatory teams the development of appropriate global and local SOP’s and working practices, to optimise the effective handling of regulatory tasks related to Alliance Healthcare product portfolio or the development of new processes necessary to deliver compliance with European and local legislation. Provide training as author and or subject matter expert where applicable.
  • Work collaboratively and build strong working relationships with central and local cross-functional teams to manage the assessment of new products and maintenance of existing products in the Alvita and Almus ranges.
  • Take a vital role in the Monthly Operational NPD Meetings with the European Business units.
Desired Qualifications
  • Additional language skill beyond fluent English; not mandatory

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE